Stocktoria
KalVista Pharmaceuticals, Inc. KALV
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2015-04-09
KalVista Pharmaceuticals, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $50.0M | — | — | — | $12.7M | $16.1M | $8.4M | $1.5M | $2.1M |
| R&D expense | $71.7M | $86.2M | $80.3M | $70.2M | $41.3M | $40.2M | $35.0M | $18.2M | $12.7M | $14.7M |
| Operating income | -$188.0M | -$140.4M | -$110.9M | -$96.6M | -$57.9M | -$40.5M | -$29.8M | -$18.7M | -$22.3M | -$15.2M |
| Income tax | $3.4M | $0 | $0 | $0 | $0 | -$124,000 | $124,000 | $0 | $0 | $0 |
| Net income | -$183.4M | -$126.6M | -$92.9M | -$82.3M | -$46.2M | -$29.1M | -$20.8M | -$15.8M | -$18.6M | -$11.4M |
| EPS (diluted) | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.42 | $-1.64 | — | — | — | — |
| Operating cash flow | -$152.9M | -$89.2M | -$75.3M | -$78.1M | -$30.2M | -$44.8M | -$36.4M | $10.6M | -$23.7M | -$13.2M |
| Free cash flow | -$153.3M | -$89.3M | -$76.5M | -$79.1M | -$30.3M | -$45.0M | -$37.4M | $9.1M | -$23.8M | -$13.2M |
| Cash & equivalents | $131.6M | $31.8M | $56.2M | $30.7M | $50.6M | $15.8M | $32.0M | $51.1M | $30.9M | $21.8M |
| Total assets | $250.8M | $235.4M | $183.2M | $203.9M | $272.0M | $92.5M | $118.1M | $61.4M | $34.3M | $24.7M |
| Shareholders' equity | $95.4M | $206.6M | $161.0M | $185.1M | $257.2M | $83.8M | $96.7M | $27.3M | $31.3M | -$37.1M |
Growth · year-over-year · Revenue CAGR 87.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | -21.3% | +92.1% | +458.1% | -29.5% | — |
| Free cash flow growth | — | — | — | — | — | — | -510.1% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001348911 · US · as of 2025-04-30. facts plus Stocktoria's own computed scores — not investment advice.